South West Clinical School Journal

South West Clinical School Journal - Issue 2, Number 1, 2022

2022

## Risk reduction and early identification of breast cancer related breast lymphoedema

#### Underwood, Emma

Underwood, E. (2022). 'Risk reduction and early identification of breast cancer related breast lymphoedema', South West Clinical School Journal, 2 (1). http://hdl.handle.net/10026.1/19729

https://doi.org/10.24382/aeb0-1113 South West Clinical School Journal University of Plymouth

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

### **South West Clinical School Journal**

Online Journal of the South West Clinical School in Cornwall ISSN 2754-9461

Special Edition

#400WORDS: CHIEF NURSE RESEARCH FELLOWSHIP EVIDENCE IMPLEMENTATION PROJECTS

# Risk reduction and early identification of breast cancer related breast lymphoedema

#### Emma Underwood<sup>1</sup>

<sup>1</sup>Lymphoedema Specialist. Royal Cornwall Hospitals NHS Trust, TRURO, TR1 3LJ, UK.

Email: <u>emmaunderwood@.nhs.net</u>

Submitted for publication: 02 February 2022

Accepted for publication: 03 March 2022

Published: 28 March 2022

#### Background

Lymphoedema is a common consequence of breast cancer treatment, which can develop in the hand, arm, breast and chest wall (DiSipio et al., 2013). Whilst the main focus of patient information is on arm lymphoedema, an audit of lymphoedema services in Cornwall reported an estimated incidence of breast lymphoedema of 16% (Underwood et al., 2021). Breast lymphoedema is associated with increased breast volume, peau d'orange, skin thickening, redness, pain, and heaviness (Verbelen et al., 2014) and can have a significant impact on the patient's mental health (Fu et al., 2013) and quality of life (Young-Afat et al., 2019). Risk reduction and early intervention advice has the potential to reduce symptom burden of this potentially chronic condition but following restrictive risk reduction guidance can have a negative psychological impact on patients (Asdourian et al., 2016). It is important, therefore, to identify patients at high risk of developing breast cancer related breast lymphoedema (BCRBL) to ensure, information is correctly targeted.

#### **Review of the evidence**

A comprehensive literature search was performed in Medline, CINAHL and PubMed databases from 2011 onwards (English, Full Text) using the search terms 'Risk Factors AND Breast Lymphoedema' and Google Scholar and Trip Database using the search term 'Breast Lymphoedema'. The literature predominantly refers to arm lymphoedema with very little literature on breast lymphoedema, demonstrating the need for more robust evidence.

Following a review of the evidence, a potential risk factor and symptom profile was developed, informed by clinical experience, and ratified by the steering group including radiotherapy, breast surgery and lymphoedema specialist clinicians. This will be used to inform an audit of patients presenting with breast cancer related lymphoedema and develop a risk factor and symptom profile. This profile will inform service provision to target those who would most benefit from risk reduction information and be used to aid early identification and screening. In addition, the literature was reviewed with regards to preventative strategies, self-management, and treatment modalities to inform development of future resources.

#### **Project plan**

The JBI Evidence Implementation Model (Porritt et al., 2020) provides structure and ensures that evidence is central to the project. This service development project aims firstly to complete an evidence-informed audit of the risk factors, symptom profile and awareness of BCRBL in breast cancer patients referred to lymphoedema services in Cornwall. Secondly, evidence-based resources will be developed in collaboration with patients and healthcare professionals. These will be targeted at the those most at risk and a screening tool for early identification implemented. Finally, the audit will be repeated to evaluate the project's impact on clinical practice.

#### References

Asdourian, M. S., Skolny, M. N., Brunelle, C., Seward, C. E., Salama, L. and Taghian, A. G. (2016) 'Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis', *The Lancet Oncology*, 17(9), pp. e392e405.

DiSipio, T., Rye, S., Newman, B. and Hayes, S. (2013) 'Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis', *The Lancet Oncology*, 14(6), pp. 500-15.

Fu, M.R., Ridner, S.H., Hu, S.H., Stewart, B.R., Cormier, J.N. and Armer, J M. (2013) 'Psychosocial impact of lymphedema: a systematic review of literature from 2004 to 2011', *Psycho-Oncology*, 22(7), pp. 1466-84.

Porritt, K., McArthur, A., Lockwood, C., Munn, Z. (2020) *JBI Handbook for Evidence Implementation.* Available at <u>https://implementationmanual.jbi.global</u> (Accessed 01/11/2021).

Underwood, E., Jones, C. and Treleaven, H. (2021) 'Breast cancer related lymphoedema an audit of incidence and management in Cornwall.', *British Lymphology Society: News & Views*, (120), pp. 22-4.

Verbelen, H., Gebruers, N., Beyers, T., De Monie, A.-C. and Tjalma, W. (2014) 'Breast edema in breast cancer patients following breast-conserving surgery and radiotherapy: a systematic review', *Breast Cancer Research And Treatment*, 147(3), pp. 463-71.

Young-Afat, D.A., Gregorowitsch, M.L., van den Bongard, D.H., Burgmans, I., van der Pol, C.C., Witkamp, A.J., Bijlsma, R.M., Koelemij, R., Schoenmaeckers, E.J., Jonasse, Y., van Gils, C.H. and Verkooijen, H.M. (2019) 'Breast Edema Following Breast-Conserving Surgery and Radiotherapy: Patient-Reported Prevalence, Determinants, and Effect on Health-Related Quality of Life', *JNCI Cancer Spectrum*, 3(2), pkz011.



This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International (CC BY-NC-SA 4.0) licence (see <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">https://creativecommons.org/licenses/by-nc-sa/4.0/</a>) which permits others to copy and redistribute in any medium or format, remix, transform and on a non-commercial basis build on this work, provided appropriate credit is given. Changes made need to be indicated, and distribution must continue under this same licence.